Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study


Por: Perez-Recio, S, Pallares, N, Grijota-Camino, MD, Sanchez-Montalva, A, Barcia, L, Campos-Gutierrez, S, Pomar, V, Rabunal-Rey, R, Balcells, ME, Gazel, D, Montiel, N, Vicente, D, Goic-Barisic, I, Schon, T, Paues, J, Marekovic, I, Cacho-Calvo, J, Barac, A, Goletti, D, Garcia-Gasalla, M, Barcala, JM, Tortola, MT, Anibarro, L, Suarez-Toste, I, Moga, E, Gude-Gonzalez, MJ, Naves, R, Karsligil, T, Martin-Penaranda, T, Stevanovic, G, Trigo, M, Rubio, V, Karaoglan, I, Bayram, N, Alcaide, F, Tebe, C, Santin, M

Publicada: 1 dic 2021
Resumen:
We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune-mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB2-TB1 value.0.6 IU.ml(-1) was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2>TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB2-TB1 result of >0.6 IU.ml(-1) and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 15.4%, and 17.7% with close, frequent, and sporadic contact had a TB2>TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB2-TB1 difference of.0.6 IU.ml(-1) was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection. IMPORTANCE Contact tuberculosis tracing is essential to identify recently infected people, who therefore merit preventive treatment. However, there are no diagnostic tests that can determine whether the infection is a result of a recent exposure or not. It has been suggested that by using the QuantiFERON-TB gold plus, an interferon gamma (IFN-gamma) release assay, a difference in IFN-gamma production between the two antigen tubes (TB2 minus TB1) of.0.6 IU.ml(-1) could serve as a proxy marker for recent infection. In this large multinational study, infected individuals could not be classified according to the risk of recent exposure based on differences in IFN- g in TB1 and TB2 tubes that were higher than 0.6 IU.ml(-1). QuantiFERON-TB gold plus is not able to distinguish between recent and remotely acquired tuberculosis infection, and it should not be used for that purpose in contact tuberculosis tracing.

Filiaciones:
Perez-Recio, S:
 Bellvitge Univ Hosp, Dept Infect Dis, TB Unit, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain

Pallares, N:
 Bellvitge Biomed Res Inst IDIBELL, Biostat Unit UBiDi, Barcelona, Spain

Grijota-Camino, MD:
 Bellvitge Univ Hosp, Dept Infect Dis, TB Unit, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain

Sanchez-Montalva, A:
 Vall dHebron Univ Hosp, Dept Infect Dis, PROSICS, Barcelona, Spain

Barcia, L:
 Complexo Hosp Univ Pontevedra, Dept Internal Med, TB Unit, Pontevedra, Spain

Campos-Gutierrez, S:
 Univ Hosp Canary Isl, Microbiol & Infect Control Serv, Tenerife, Canary Islands, Spain

Pomar, V:
 Hosp Santa Creu & Sant Pau, Infect Dis Unit, Dept Internal Med, Barcelona, Spain

Rabunal-Rey, R:
 Hosp Lucus Augusti, Dept Internal Med, Infect Dis Unit, Lugo, Spain

Balcells, ME:
 Pontificia Univ Catolica Chile, Sch Med, Dept Infect Dis, Santiago, Chile

Gazel, D:
 Gaziantep Univ, Dept Med Microbiol, Fac Med, Gaziantep, Turkey

Montiel, N:
 Hosp Costa del Sol, Dept Microbiol, Malaga, Spain

 Hosp Univ Puerta Mar, Dept Microbiol, Cadiz, Spain

Vicente, D:
 Hosp Univ Donostia, Dept Microbiol, San Sebastian, Spain

Goic-Barisic, I:
 Univ Hosp Split, Dept Clin Microbiol, Split, Croatia

 Univ Split, Sch Med, Split, Croatia

Schon, T:
 Linkoping Univ, Kalmar Cty Hosp, Dept Infect Dis, Kalmar, Linkoping, Sweden

 Linkoping Univ, Dept Biomed & Clin Sci, Div Infect Dis, Linkoping, Sweden

Paues, J:
 Linkoping Univ, Dept Biomed & Clin Sci, Div Infect Dis, Linkoping, Sweden

Marekovic, I:
 Univ Hosp Ctr Zagreb, Dept Clin & Mol Microbiol, Zagreb, Croatia

Cacho-Calvo, J:
 Getafe Univ Hosp, Dept Microbiol, Madrid, Spain

Barac, A:
 Clin Ctr Serbia, Clin Infect & Trop Dis, Belgrade, Serbia

 Univ Belgrade, Fac Med, Belgrade, Serbia

Goletti, D:
 Ist Nazl Malattie Infett Lazzaro Spallanzani IRCC, Rome, Italy

Garcia-Gasalla, M:
 Hosp Univ Son Llatzer IdISBa, Dept Internal Med, Infect Dis Unit, Palma De Mallorca, Illes Balears, Spain

 Hosp Univ Son Espases IdISBa, Dept Internal Med, Infect Dis Unit, Palma De Mallorca, Illes Balears, Spain

Barcala, JM:
 Hosp Univ Jerez, Infect Dis Unit, Cadiz, Spain

Tortola, MT:
 Vall dHebron Univ Hosp, Dept Microbiol, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Genet & Microbiol, Barcelona, Spain

Anibarro, L:
 Complexo Hosp Univ Pontevedra, Dept Internal Med, TB Unit, Pontevedra, Spain

Suarez-Toste, I:
 Univ Hosp Canary Isl, Pneumol Serv, Tenerife, Canary Islands, Spain

Moga, E:
 Hosp Santa Creu & Sant Pau, Dept Immunol, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain

Gude-Gonzalez, MJ:
 Hosp Lucus Augusti, Dept Microbiol, Lugo, Spain

Naves, R:
 Univ Chile, Fac Med, Inst Biomed Sci, Program Immunol, Santiago, Chile

Karsligil, T:
 Gaziantep Univ, Dept Med Microbiol, Fac Med, Gaziantep, Turkey

Martin-Penaranda, T:
 Hosp Univ Donostia, Dept Microbiol, San Sebastian, Spain

Stevanovic, G:
 Clin Ctr Serbia, Clin Infect & Trop Dis, Belgrade, Serbia

 Univ Belgrade, Fac Med, Belgrade, Serbia

Trigo, M:
 Complexo Hosp Univ Pontevedra, Microbiol Dept, Pontevedra, Spain

Rubio, V:
 Hosp Santa Creu & Sant Pau, Infect Dis Unit, Dept Internal Med, Barcelona, Spain

 Hosp Municipal Badalona, Dept Internal Med, Barcelona, Spain

Karaoglan, I:
 Gaziantep Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Gaziantep, Turkey

Bayram, N:
 Gaziantep Univ, Dept Pulm Dis, Fac Med, Gaziantep, Turkey

Alcaide, F:
 Bellvitge Univ Hosp, Dept Microbiol, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain

 Univ Barcelona, Dept Pathol & Expt Therapy, Barcelona, Spain

Tebe, C:
 Bellvitge Biomed Res Inst IDIBELL, Biostat Unit UBiDi, Barcelona, Spain

Santin, M:
 Bellvitge Univ Hosp, Dept Infect Dis, TB Unit, Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain

 Univ Barcelona, Dept Clin Sci, Barcelona, Spain
ISSN: 21650497
Editorial
AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 9 Número: 3
Páginas:
WOS Id: 000736124700071
ID de PubMed: 34756079
imagen hybrid, Green Published

MÉTRICAS